AdhexPharma
AdhexPharma is an independent pharmaceutical company specializing in the development and manufacturing of patches and oral films. With over 40 years of experience, they offer comprehensive drug delivery solutions from drug development to market, including contract development, manufacturing, licensing, analytical services, and innovative drug delivery systems like oral films and transdermal patches. They are committed to innovation, quality, and sustainability, with a focus on patient-friendly, efficient, and customizable drug delivery technologies.
Industries
Nr. of Employees
medium (51-250)
AdhexPharma
Chenôve, Bourgogne-Franche-Comté, France
Products
Oral thin films (fast-dissolving and oromucosal films)
Thin-film dosage forms for rapid dissolution or mucosal absorption, enabling precise dosing and administration without water; suitable for pediatric and dysphagia populations.
Planar patches (transdermal and topical matrix/impregnated patches)
Topical and transdermal patches engineered for controlled skin delivery and sustained systemic exposure, available in multiple architectures to meet release and stability requirements.
Contract Manufacturing Services
Comprehensive contract manufacturing services for pharmaceutical patches and oral films, covering product transfers, formulation evaluation, scale-up, and commercial production.
Licensing Opportunities
Licensing services designed to unlock the potential of existing drug portfolios in patch and oral film formats.
Zeqmelit®
Dexamethasone oral film available for licensing.
Oral films
Fast dissolving, buccal or sublingual oral films.
Oral thin films (fast-dissolving and oromucosal films)
Thin-film dosage forms for rapid dissolution or mucosal absorption, enabling precise dosing and administration without water; suitable for pediatric and dysphagia populations.
Planar patches (transdermal and topical matrix/impregnated patches)
Topical and transdermal patches engineered for controlled skin delivery and sustained systemic exposure, available in multiple architectures to meet release and stability requirements.
Contract Manufacturing Services
Comprehensive contract manufacturing services for pharmaceutical patches and oral films, covering product transfers, formulation evaluation, scale-up, and commercial production.
Licensing Opportunities
Licensing services designed to unlock the potential of existing drug portfolios in patch and oral film formats.
Zeqmelit®
Dexamethasone oral film available for licensing.
Oral films
Fast dissolving, buccal or sublingual oral films.
Services
Feasibility assessment, formulation development, analytical development and production of clinical trial supplies at pilot or commercial-representative scale.
Commercial cGMP manufacturing of oral films and transdermal/topical patches with capacity for high-volume production and handling of controlled substances.
Analytical method development, validation, routine QC, release testing and stability studies including specialized assays for permeation and film-specific properties.
Pilot production, technology transfer and process optimization to replicate commercial parameters and support validation and commercial batches.
Strategic life-cycle planning, reformulation and licensing of developed formulations and market-ready products to third parties.
Feasibility assessment, formulation development, analytical development and production of clinical trial supplies at pilot or commercial-representative scale.
Commercial cGMP manufacturing of oral films and transdermal/topical patches with capacity for high-volume production and handling of controlled substances.
Analytical method development, validation, routine QC, release testing and stability studies including specialized assays for permeation and film-specific properties.
Pilot production, technology transfer and process optimization to replicate commercial parameters and support validation and commercial batches.
Strategic life-cycle planning, reformulation and licensing of developed formulations and market-ready products to third parties.
Expertise Areas
- Transdermal patch design and manufacturing
- Oral thin-film formulation and route-specific design (orodispersible, buccal, sublingual)
- Integrated CDMO services from feasibility to commercial supply
- Analytical method development, QC and stability testing for planar dosage forms
Key Technologies
- Hot-melt extrusion (HME)
- Solvent casting for thin-film manufacturing
- Drug-in-adhesive, reservoir, matrix and micro-reservoir patch architectures
- Orodispersible, buccal and sublingual film platforms
News & Updates
AdhexPharma is focusing on soft mobility to reduce its carbon footprint and improve its employees' quality of life, with actions like cycling incentives, electric vehicle infrastructure, and public transport partnerships.
AdhexPharma achieved a remarkable ranking of 171st in the Financial Times' list of Europe’s Long-Term Growth Champions, highlighting its consistent growth and leadership in the pharmaceutical industry.
AdhexPharma announced a major expansion with a new 8,000m² facility in Chenôve, France, focusing on innovation, sustainability, and energy efficiency, including renewable energy and heat recovery systems.
Labtec GmbH contributed to a publication on a soft skin adhesive patch for burn wounds, showcasing its expertise in drug delivery systems and support for medical solutions.
AdhexPharma acquired tesa Labtec GmbH, a CDMO specializing in transdermal and topical patches and films, strengthening its presence in Germany and expanding its technological capabilities.
Labtec GmbH appointed Ralf Kibele as Managing Director, emphasizing its role in drug delivery solutions and collaboration with AdhexPharma.
AdhexPharma is focusing on soft mobility to reduce its carbon footprint and improve its employees' quality of life, with actions like cycling incentives, electric vehicle infrastructure, and public transport partnerships.
AdhexPharma achieved a remarkable ranking of 171st in the Financial Times' list of Europe’s Long-Term Growth Champions, highlighting its consistent growth and leadership in the pharmaceutical industry.
AdhexPharma announced a major expansion with a new 8,000m² facility in Chenôve, France, focusing on innovation, sustainability, and energy efficiency, including renewable energy and heat recovery systems.
Labtec GmbH contributed to a publication on a soft skin adhesive patch for burn wounds, showcasing its expertise in drug delivery systems and support for medical solutions.
AdhexPharma acquired tesa Labtec GmbH, a CDMO specializing in transdermal and topical patches and films, strengthening its presence in Germany and expanding its technological capabilities.
Labtec GmbH appointed Ralf Kibele as Managing Director, emphasizing its role in drug delivery solutions and collaboration with AdhexPharma.